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Abstract
We develop mathematical models for the role of hepatitis B e-antigen in creating immunological tolerance during hepatitis
B virus infection and propose mechanisms for hepatitis B e-antigen clearance, subsequent emergence of a potent cellular
immune response, and the effect of these on liver damage. We investigate the dynamics of virus-immune cells interactions,
and derive parameter regimes that allow for viral persistence. We modify the model to account for mechanisms responsible
for hepatitis B e-antigen loss, such as seroconversion and virus mutations that lead to emergence of cellular immune
response to the mutant virus. Our models demonstrate that either seroconversion or mutations can induce immune
activation and that instantaneous loss of e-antigen by either mechanism is associated with least liver damage and is
therefore more beneficial for disease outcomes.
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Introduction
Infection with Hepatitis B virus (HBV) leads to asymptomatic
self-limiting infections in most immunocompetent adult infections
and chronic infections in perinatal, early childhood, and immuno-
compromised adult infections [1–3]. Perinatal vertical transmis-
sion from mothers that have HBV e-antigen (HBeAg) in their
serum is associated with high infectivity [4]. Successful clearance
of HBV virus is believed to be immune mediated, with combined
innate, cellular and humoral immune responses playing a role in
disease outcome [5–8]. In contrast, perinatal chronic HBV
infections are characterized by high HBV DNA in serum, the
presence of hepatitis B e-antigen, and normal alanine amino-
transferase (ALT) levels which indicate limited killing of infected
liver cells by the immune system [9,10]. The absence of liver
disease in chronic patients is attributed to the immunoregulatory
functions of HBeAg, which serves as a tolerogen by inactivating
HBeAg-specific T-cells through clonal deletion, ignorance, and
anergy [11–13].
Spontaneous HBeAg loss marks transition from immune
tolerance to immune clearance phase and is considered a
beneficial event for disease prognosis, especially when it occurs
at an early age [14]. Two mechanisms of HBeAg loss have been
proposed: HBeAg seroconversion through emergence of an anti-
HBe antibody (HBeAb) [9,14–16] and mutations in the core
promoter or precore region of HBV genome that affect HBeAg
production leading to emergence of predominant HBeAg-negative
virus strains [17–19]. The immune activation phase is character-
ized by increased ALT levels, necrotic inflammatory activity, and
loss of circulating HBeAg. These events are correlated with
exacerbation of liver injury and risk of progressing to cirrhosis of
the liver and to hepatocellular carcinoma [9,18,20]. Following
HBeAg loss most patients enter an inactive phase where ALT
levels are normal, HBV DNA is small, and there is minimal liver
damage [9]. However, relapses in active HBV replication with
HBeAg negative virus may arise, which may be correlated to initial
age of HBeAg loss [14,21]. These relapses are followed by ALT
flares and moderate to severe liver damage [21].
The management of chronic HBV infection requires further
understanding of the host-virus interactions leading to viral
persistence. We aim to understand the role of HBeAg in creating
immunological tolerance, the events leading to HBeAg clearance,
subsequent emergence of potent cellular immune response, and
the extent of liver damage. To provide insight into these
mechanisms we develop mathematical models of cellular immune
responses to a wild type HBeAg-positive virus and investigate
interactions and parameter regimes that allow for viral persistence
and eventual immune reactivation. Previous models have studied
the dynamics of HBV clearance during acute infections [22–24],
the decay profiles of HBV levels during drug therapy in chronic
infections [25–28], and the roles of immune responses in HBV
pathogenesis [29–31].
In this study we use mathematical models to investigate the
mechanisms leading to establishment of chronic hepatitis B
infection and aim to understand how the presence of circulating
HBeAg creates immunological tolerance. We derive and analyze a
mathematical model of e-antigen induced T-cell anergy in an
HBeAg-positive HBV infection. We then expand the model to
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cells become activated as a result of e-antigen seroconversion or
HBeAg-positive virus mutation. In the seroconversion scenario, we
determine the antibody levels required to successfully restore
effector function to anergic T-cells. A prediction of our model is
that sudden loss of e-antigen through induction of high antibody
levels is beneficial to the host as it reduces overall liver cell death.
While seroconversion is considered an important stage in HBV
clearance [14], the mechanism of seroconversion is unknown and
it is difficult to predict when it will occur. Studies have found a
correlation between seroconversion and core and precore muta-
tions in HBeAg-positive virus [18]. We expand our model to
account for mutations from HBeAg-positive to HBeAg-negative
virus strains and investigate the composition of the overall virus
population under different mutation regimes. We determine that
intermediate mutation rates giving rise to mixed e-antigen positive
and negative virus populations are associated with high levels of
liver cell death, while complete loss of HBeAg-positive virus strains
is associated with mild liver disease and low HBeAg-negative virus
levels, corresponding to inactive stages of HBV infection [9].
These results provide a clearer picture of the long-term hepatitis B
virus dynamics and of the extent of liver disease following immune
activation.
Models and Methods
Model of HBeAg mediated chronic HBV infection
Let VP be HBeAg-positive virus concentration, e be HBeAg
concentration and Tp be the concentration of HBeAg-specific T-
cells. Following infection with the virus, liver cells start producing
new virions. We simplify the viral life-cycle, aggregating the
processes of infection and host-cell viral production into a simple
replication model in which viruses divide with a per-capita rate, rp,
and a maximum carrying capacity, K. e is produced at rate p per
virus per day and is cleared at rate d per day. Tp are activated
upon encounter with antigen, clonally expand and differentiate
into cytotoxic killer cells at rate ap, and have an average lifespan of
1=d days. We model immunological tolerance by inhibiting the T-
cell expansion by a maximum quantity se. Finally, virus is
removed by immune cells at rate mp. As immune cells do not kill
virus directly, we assume that virus is in quasi-equilibrium with
infected liver cells. The dynamics of the model are given by the
following system:
dVp
dt
~rpVp 1{
Vp
K
  
{mpVpTp, ð1Þ
de
dt
~pVp{de, ð2Þ
dTp
dt
~
apVpTp
1zse
{dTp: ð3Þ
System (1–3) has three steady states: a biologically irrelevant
steady state, S0~(0,0,0), a state representing immune tolerance,
ST~(~ V Vp,~ e e,~ T Tp)~ K,
Kp
d
,0
  
, and a state representing immune
activation, SL~(  V Vp,  e e,  T Tp)~ V,
pV
d
,
rp
mp
1{
V
K
    !
; where
V~
dd
apd{dsp
. These states correspond to liver failure, im-
mune-tolerant chronic infection and immune-competent chronic
infection respectively.
S0 is always unstable. If
0wV or VwK, ð4Þ
ST is asymptotically stable and SL does not exist. If 0vVvK
then ST is unstable and SL exists and is asymptotically stable.
From here on we will refer to (4) as the tolerance conditions.
Model for loss of HBeAg due to seroconversion
Several papers have documented the emergence of an anti-HBe
antibody that binds e-antigen and enhances its removal [9,14–16].
We model loss of e-antigen due to HBeAg-specific antibodies by
increasing HBeAg clearance rate in equation (2) to account for
antibody-mediated removal:
de
dt
~pVp{d(1zcIg)e: ð5Þ
Ig represents HBeAb concentration, which we assume constant
and equal to its maximal size and c is the antibody-mediated
HBeAg removal rate. The modified system still has the biologically
irrelevant steady state, S0~(0,0,0), and the immune tolerance
steady state, STs~ K,
Kp
d
,0
  
. The immune activation steady
state becomes SLs~(  V Vps,  e es,  T Tps)~ VIg,
pVIg
d
,
rp
mp
1{
VIg
K
    !
,
where VIg~
dd(1zcIg)
apd(1zcIg){dsp
. Notice that VIg~V when Ig~0.
SLs exists and is asymptotically stable when 0vVIgvK.
Following seroconversion, tolerance, represented by (4), is lost
when enough HBeAg-specific antibody is present to make
0vVIgvK.
Model for loss of HBeAg-positive virus through
mutations
Mutations in the hepatitis B virus core promoter region [32] or
precore region [33] may affect HBeAg production leading to the
emergence of HBeAg-negative virus strains and subsequent
activation of T-cell clones that are specific for such virus [17].
We model this process by expanding system (1–3) to account for
the emergence of HBeAg-negative virus concentration, Vn, and
the corresponding T-cell response, Tn. We assume that starting at
time t~tc a continuous percent w of the reproducing virus strain
Vp mutates into virus Vn. The T-cell response to the HBeAg-
negative virus arises at t~tc as well. The new system is given by:
dVp
dt
~rpVp (1{w){
VpzVn
K
  
{mpVpTp, ð6Þ
dVn
dt
~rnVn 1{
VpzVn
K
  
zrpwVp{mnVnTn, ð7Þ
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dt
~pVp{de, ð8Þ
dTp
dt
~
apVpTp
1zse
{dTp, ð9Þ
dTn
dt
~
anVnTn
1zse
{dTn, ð10Þ
where the dynamics of Tp and e are as before. Viruses of strain i
are produced at rates ri and removed at rates mi by their strain-
specific T-cell responses (i[fp,ng). Upon encountering HBeAg-
negative virus, Tn expands at rate an and is inhibited by the e-
antigen by a maximum quantity se. Their average lifespan is 1=d
days. For simplicity we assume that the two viruses have the same
fitness rates rn~rp and the same removal by immune system rates
mn~mp.
The mutation model has several steady states. The first one is
biologically irrelevant, S0~(0,0,0,0,0): The tolerance state of (6–
10) is depicted by the absence of T-cell induced killing of Vn when
Vp is lost completely, STn~(0,K,0,0,0):
There are four steady states that represent immune activation.
The first one represents immune activation against Vp but not Vn,
SL1~ V,  V V1,
p
d
V,  t t1,0
  
, where   V V1 and   t t1 are defined in
Supporting Information S1. SL1 exists when 0vVvK and
wv1{
Vz  V V1
K
.
There are two steady states representing competent T-cell
response to Vn but not Vp: one corresponding to small and
intermediate percentage of Vp mutations,
SL2~   q q2,  V V2,
p
d
  q q2,0,  s s2
  
which exists and is asymptotically stable
when 1{
V
K
1z
ap
an
  
vwv1{
d
anK
(0vwv1{
d
anK
when
tolerance condition (4) is satisfied); and one corresponding to
large percentage of mutations leading to complete removal of Vp,
SL3~ 0,  V V3,0,0,  s s3
  
, which exists when Kanwd and is asymptot-
ically stable when ww1{
d
Kan
.
The last steady state corresponds to T-cells response to both
viruses types, SL4~ V,
ap
an
V,
p
d
V,  t t4,  s s4
  
which does not exist
when 0wVwK.   q qi,  V Vi,  t ti,  s si (i[1,2,3,4) are defined in Supporting
Information S1.
Under the tolerance condition (4) the only steady states that
exist and can be stable are STn, SL2 and SL3 (for detailed analysis
see Supporting Information S1).
Initial data and immune tolerance
For model (1–3) we assume that the initial inoculum contains
small concentrations of HBeAg-positive virus and circulating
HBeAg (Vp(0)~0:3 per ml, e(0)~0:03 per ml). In the absence of
infection the concentration of HBeAg-specific T-cells is Tp(0)~10
cells per ml.
For model (6–10), we assume initial concentrations of
Vp(0)~0:3 virus per ml, e(0)~0:03 per ml, and Tp(0)~10 cells
per ml, as in the initial model (1–3). Moreover, HBeAg-negative
virus and corresponding T-cells are absent, i.e. Vn(t)~0,
dVn=dt(t)~0, Tn(t)~0, and dTn=dt(t)~0 for tvtc. Therefore,
for 0vtvtc, the dynamics of (6–10) are identical to the dynamics
of (1–3), with the immune tolerant state K,0,
Kp
d
,0,0
  
being
asymptotically stable when tolerance conditions (4) are satisfied. At
t~tc mutations start. We model this by the emergence of positive
concentrations of Vn and Tn in the body, i.e. Vn(tc)~0:3 per ml
and Tn(tc)~10 cells per ml (similar dynamics will be achieved if
Vn(tc)~Tn(tc)~0). The rest of the variables are computed by
solving (6–10) at time t~tc. We study the conditions needed for
the loss of tolerance under this scenario.
Results
Immune tolerance
The presence of circulatory HBeAg can induce clonal anergy
characterized by the inability of HBeAg-specific T-cells to grow,
maturate, and acquire effector function such as cytokine produc-
tion [11–13]. Analytical results show that this is represented by
parameters of model (1–3) satisfying conditions (4). We rewrite
them to study the effect of the HBeAg:
Vv0 uapKvds~ e e,
VwK uds~ e evapKvd(1zs~ e e),
ð11Þ
where ~ e e is the steady state concentration of e-antigen during
immune tolerance. Biologically, our model predicts that when the
maximal activation of the immune cells is smaller than immune
cells removal rate at the peak of e-antigen inhibition or smaller
than the combined effect of natural death rate and removal rate at
the peak of e-antigen inhibition then the immune cells are lost.
The virus replicates and settles at high levels of 108 HBV copies
per ml. Inequality (11) provides an estimate for the e-antigen levels
required for induction of T-cell tolerance.
An extreme case describing this scenario is represented by the
failure of T-cells to differentiate,   a ap~ap=s?0 (in particular
ap~0) and would correspond to HBeAg-specific T-cell ignorance.
This is in agreement with experimental observations [11]. Under
the ap~0 assumption, system (1–3) has only two steady states: ST,
which is always stable, and S0, which is always unstable.
Increased CTL production leads to loss of tolerance
Since the loss of tolerance is marked by an increase in HBeAg-
specific T-cell levels, we first explore the causes of this increase. In
our model, immune recovery is represented by change in stability
from the tolerance steady state ST to the immune activation steady
state SL. This can occur when either the differentiating rate of
HBeAg-specific T-cells (ap) increases or the inhibition of differen-
tiation due to HBeAg (s) decreases causing
apKwd(1zs~ e e): ð12Þ
Biologically, this means that when the maximal activation of
HBeAg-specific T-cells is bigger than the combined effect of their
natural death rate and the death rate at the peak of e-antigen
inhibition then the tolerance is lost and the immune cells start
removing virus. Condition (12) is independent of the size of the
immune cells killing rate (mp), which means that the presence of
HBeAg does not affect directly the killing capacity of HBeAg-
specific T-cells.
The temporal transition from immune tolerance to immune
activation is presented in figure 1. High HBeAg-positive virus
concentration of 108 copies per ml decrease to below 106 copies
Role of E-Antigen in HBV Chronic Infection
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T-cells (lower panel, dashed line) get activated (lower panel, solid
line). The loss of tolerance is marked by vertical lines.
Notice that (12) also suggests that tolerance can be lost due to a
net decrease in the HBeAg production. To place this on solid
biological ground, we consider HBeAg seroconversion.
Loss of HBeAg due to seroconversion leads to immune
activation
Analytical investigation of model (1–3) with e-antigen equation
modified to (5) states that when Vv0 and 0vVIgvK, we observe
immune tolerance for small antibody levels (IgvIgcrit) and
immune activation and killing in the presence of potent antibody
response (Ig§Igcrit) (see figures 2 and S1). Note that a high
antibody removal rate is necessary for the HBeAg-specific T-cells
to reach steady-state values. When VwK and 0vVIgvK we
observe immediate immune activation and killing even for low
antibody levels, i.e. Ig§Igcrit&0.
For both cases (Vv0 or VwK), the critical antibody response
needed for HBeAg-specific T-cells to reach equilibrium levels is
given by
Igcrit~
spdK
(apK{d)d
{1^
spdK
(apK{d)d
: ð13Þ
It should be mentioned that Igcrit=p is the same for Vv0 or
VwK. Since Vv0 corresponds to higher levels of HBeAg
production p, higher antibody levels are needed for immune
activation to occur, i.e Igcrit is bigger in the Vv0 than in the
VwK.
Biologically, immune tolerance occurs when maximal activation
of HBeAg-specific T-cell is lower than the combined effect of their
natural death rate and death rate at the peak of HBeAg inhibition.
Immune tolerance is lost when maximal activation of HBeAg-
specific T-cell exceeds the combined effect of their natural death
rate and death rate at the peak of HBeAg inhibition in the
presence of HBeAg-specific antibodies. Temporal evolution of the
HBeAg-positive virus, HBeAg, and HBeAg-specific T-cell con-
centrations prior and following seroconversion are presented in
figure 3. We see that when antibodies bind HBeAg (vertical lines),
hepatitis B virus decays from 108 virions per ml (top panel, dashed
line) to 5|106 virions per ml (top panel, solid line). At the same
time, low HBeAg-specific T-cell levels seen before seroconversion
(bottom panel, dashed line) start increasing to positive steady state
values following removal of HBeAg (bottom panel, solid line).
Loss of HBeAg-positive virus through mutations
Mutations in the hepatitis B virus core promoter region [32] or
precore region [33] may affect HBeAg production leading to the
emergence of HBeAg-negative virus strains and subsequent
activation of T-cell clones that are specific for such virus [17].
We used the two virus model presented in the methods section to
study this possibility.
Analytical results show that there are three states that exist and
can be stable under the tolerance condition (4): immune tolerance
to virus Vn when Vp completely mutates (STn), competent T-cell
response to Vn but not Vp when small and intermediate
Figure 1. Numerical curves given by model (1–3) showing the temporal evolution from tolerance (dashed lines) to immune
activation (solid lines) when the activation parameter ap is increased from 10{7 to 10{6. The transition point is marked by vertical lines.
The other parameters are as listed in table 1.
doi:10.1371/journal.pone.0039591.g001
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complete loss of Vp (SL3).
Analytical results show that the immune response to the mutant
virus, Tn, cannot persist and the tolerance is not lost when the T-
cell activation rate at the carrying capacity of the virus is smaller
than the T-cell death rate (anKvd). Virus population consists
exclusively of HBeAg-negative virus who reached its carrying
capacity (see figure S2).
When the activation rate at the carrying capacity of the virus is
larger than the T-cell death rate (anKwd), the tolerance state STn
becomes unstable and the immune response to the mutant virus,
Tn, reaches a positive concentration. Analytical results predict
that, depending on several factors, partial or complete loss of
HBeAg occurs. When the replication rate of the HBeAg-positive
virus exceeds the virus loss due to competition with HBeAg-
negative virus, rp(1{w)w
rp
K
d
an
, the two viruses will coexist (see
figure 4) and SL2 is stable. The overall virus population st steady
state is 3|107 HBV per ml (first two panels, solid lines) compared
to the 108 HBeAg-positive HBV per ml in the tolerant stage (top
panel, dashed line). There is no HBeAg-specific T-cell response
(forth panel, solid line), but a potent T-cell response to HBeAg-
negative virus emerges (bottom panel, solid line).
Conversely, when the replication rate of the HBeAg-positive
virus is smaller than virus loss due to competition with the HBeAg-
negative virus, rp(1{w)v
rp
K
d
an
, then, at steady state, the HBeAg-
positive virus is eliminated (see figure 5, top panel, solid line), SL3
becomes stable, and the emerging HBeAg-negative virus reaches a
low steady state of 5|104 HBV per ml (see figure 5, second panel,
solid line). This corresponds to an inactive carrier state [9]. There
is no T-cell response to the HBeAg-positive virus (forth panel, solid
line), but a potent T-cell response to HBeAg-negative virus
emerges (bottom panel, solid line).
Liver Damage due to Seroconversion
Following seroconversion with critical antibody levels, both
HBeAg and HBeAg-positive virus decrease but are not completely
eliminated. At the same time, HBeAg-specific T-cells are activated
and start killing the virus. Transition from immune ignorance to
immune activation is almost instantaneous and accounts for the
loss of more than 95% of the virus (under parameter values
presented in table 1). To determine the extent of liver injury
corresponding to virus loss following seroconversion we assume
that the infected cells (hepatocytes), H 
p, are in quasi-equilibrium
with the virus:
H 
p~
cVp
p
~fVp, ð14Þ
where c is the virus clearance rate per day, p is the number of
viruses produced by an infected cell per day, and f~c=p is the
number of infected cells per virus.
During the tolerance phase, fK hepatocytes per ml are infected
at steady state. Following seroconversion, this amount is reduced
and, at steady state, it reaches f
dd(1zcIg)
apd(1zcIg){dsp
hepatocytes
per ml. For parameters values listed in table 1, c~0:67 per day
Figure 2. Bifurcation diagrams showing the change in the steady states of HBeAg-positive virus (top panel) and HBeAg-specific T-
cells (lower panel) as a function of antibody levels (Ig) for Vv0. We used the parameter values listed in table 1, p~5:9|10{6
and c~1. The values for Vps and Tps are given by steady state values STs for IgvIgcrit and SLs for IgwIgcrit, and the transition from tolerance to
immune activation at Ig~Igcrit is marked by vertical lines.
doi:10.1371/journal.pone.0039591.g002
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PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e39591Figure 3. Numerical curves showing the temporal evolution from tolerance given by model (1–3) (dashed lines) to immune
activation due to seroconversion given by model (1-5-3) (solid lines). The transition point is marked by vertical lines. The parameters are as
in table 1, c~1, and Ig~1000.
doi:10.1371/journal.pone.0039591.g003
Figure 4. Numerical curves showing the transition from an immune tolerant HBeAg-positive virus Vp virus given by ST stable in
model (1–3) (dash lines) to an HBeAg-negative virus mediated immune activation state under small and intermediate mutation
rates corresponding to SL2 stable in model (6–10) (solid lines). The transition is marked by vertical lines. Parameters are rp~1, rn~1,
mp~10{1, mn~10{1, p~5:9|10{8, d~0:3, ap~10{7, an~10{5, s~1, d~0:5, w~0:7 and K~108. The tolerance steady states of the one-virus
model are used as initial conditions for the two virus model with Vn(500)~0:3 and Tn(500)~10.
doi:10.1371/journal.pone.0039591.g004
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there are 6:7|105 infected hepatocytes per ml at steady state
during immune tolerance and 3:35|104 infected hepatocytes per
ml at steady state during immune activation. This corresponds to a
loss of less than 5% of the liver (where the liver size is estimated as
containing L~13:6|106 hepatocytes per ml).
Since the immune activation does not lead to viral eradication,
the HBeAg-specific T-cells will continue to kill liver cells over time.
The cumulative hepatocyte loss on the first t days is given by
as(t)~
ðt
0
mpfVp(t)Tp(t)dt, ð15Þ
where t~0 is the time when antibody levels become positive,
Igw0. As the immune cell population Tp is small (but non-zero),
the cumulative hepatocyte loss as(t) is nonzero as well for solutions
of system (1-5-3) with IgvIgcrit. However, we observe significant
liver damage only after IgwIgcrit.
As expected, the amount of liver damage will increase with the
time spent in the activation stage. Numerical simulations of the
relationship between liver damage and fixed antibody levels
(figure 6) show that intermediate antibody levels accounts for the
strongest hepatocyte removal. Cumulative hepatocytes loss satu-
rates to lower values as antibody concentration increases.
Therefore, induction of high antibody levels is more beneficial
for the patient as it leads to less liver damage.
Liver Damage due to Mutations
During mutation from HBeAg-positive into HBeAg-negative
virus, tolerance is lost when the activation rate of T-cells specific
for HBeAg-negative virus at the carrying capacity of the virus is
bigger that the T-cell death rate. This is true for all mutation
percentages and independent of our starting point Vv0 or VwK.
For low and intermediate mutation rates, virus Vp is still present
and mutates continuously into Vn. The cumulative hepatocyte loss
on the first t days is
asm(t)~
ðt
0
mpfVp(t)Tp(t)zmnfVn(t)Tn(t)
  
dt, ð16Þ
where t~0 is the time of immune activation due to mutation. The
maximum hepatocyte loss occurs for intermediate mutation rates
(see figure 7 top panel).
For high mutations rates, the HBeAg-positive virus is lost at a
slow rate. Many years of continuous mutation at high rate are
needed before HBeAg-positive virus is completely eliminated.
When HBeAg-positive virus is completely replaced by HBeAg-
negative virus, the mutant virus persists at low levels   V V3~d=an.
The cumulative hepatocyte loss on the next t days following
HBeAg-positive virus elimination is
ahm(t)~
ðt
0
mnfVn(t)Tn(t)dt~tfrp
d
an
1{
d
Kan
  
: ð17Þ
The overall hepatocyte death when only Vn is present is small
compared to the overall hepatocyte death when the virus
population still contains Vp (see figure 7 bottom panel).
Our model predicts that the liver loss is compensated by the
proliferation of hepatocytes,
p(t)~
ðt
0
(rpH 
p(t)zrpH 
n)1 {
H 
pzH 
n(t)
L
  
dt, ð18Þ
where H 
p and H 
n are hepatocytes infected with the e-antigen
positive and negative virus strains. In spite of this compensation,
Figure 5. Numerical curves showing the transition from an immune tolerant HBeAg-positive virus Vp virus given by ST stable in
model (1–3) (dash lines) to an HBeAg-negative virus mediated immune activation state under large mutation rates corresponding
to SL3 stable in model (6–10) (solid lines). The transition is marked by vertical lines. Parameters are as in figure 4 and w~0:9997. The
tolerance steady states of the one-virus model are used as initial conditions for the two virus model with Vn(500)~0:3 and Tn(500)~10.
doi:10.1371/journal.pone.0039591.g005
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in the host genome that could result in genetic alterations,
chromosomal rearrangements, activation of oncogenes, inactiva-
tion of tumor suppressor genes, and ultimately to hepatocellular
carcinoma as seen in many patients with chronic hepatitis [34].
Discussion
We formulated a model of immune tolerance during chronic
infection with hepatitis B virus. The model considers the
interaction between HBeAg-positive hepatitis B virus, HBeAg,
and HBeAg-specific T-cells. We derived conditions under which
Table 1. Variable and parameter values used for simulations.
Variable Description Units
Vp e-antigen positive HBV ml
21
Vn e-antigen negative HBV ml
21
e e-antigen ml
21
Tp T-cells specific for e-antigen positive HBV ml
21
Tn T-cells specific foe e-antigen negative HBV ml
21
Ig e-antigen specific antibody ml
21
Parameter Description Values References
rp =r n HBV production rate 1 day
21 [30]
K HBV carrying capacity 108 ml
21 [9]
ap Tp activation rate 10{7 ml day
21
an Tn activation rate 10{5 ml day
21
p e-antigen production rate 5.9610
28 day
21
d e-antigen degradation rate 0:3 day
21
mp = mn immune mediated killing 0.1 ml day
21
s strength of e-antigen inhibition 1 ml
d immune cells death rate 0.5 day
21 [41]
c antibody-mediated removal rate 1 ml
w mutation percentage Varies
doi:10.1371/journal.pone.0039591.t001
Figure 6. Cumulative % liver loss as a function of antibody Ig for Vv0. The liver loss is computed as a(t)/L where a is given by (15),
L~13:6|106 represents the total hepatocytes concentration in the liver and t~100. The rest of parameters are given in table 1.
doi:10.1371/journal.pone.0039591.g006
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efficiently expand and control the infection and investigated
whether loss of HBeAg can lead to immune activation, virus
removal, and eventual liver damage. We modified the model to
account for two possible biological scenarios of HBeAg loss: the
sudden production of HBeAg specific antibodies, and the mutation
from HBeAg-positive to HBeAg-negative hepatitis B virus strains.
Our models demonstrate that either seroconversion or muta-
tions can cause loss of tolerance. In the seroconversion model,
immune tolerance is lost when Ig§Igcrit, where Igcrit is
proportional to the HBeAg production rate. When high levels of
e-antigen are produced every day, HBeAg-specific T-cell response
is so weak that its activation at the virus carrying capacity is
smaller than the immune cells death rate (V , 0). In this case,
large levels of HBeAg-specific antibodies are needed for immune
activation to occur. When lower levels of e-antigen are produced
every day, the HBeAg-specific T-cell activation rate at the virus
carrying capacity is greater than the death rate but smaller than
the combined effect of their natural death rate and death rate at
the peak of HBeAg inhibition (V . K), small levels of HBeAg-
specific antibodies are needed for immune activation to occur. We
predict increased liver damage when the minimum amount of
antibody needed for immune activation is present (with the highest
damage being done for the Vv0 parameter space) and decreased
liver loss when high antibody levels are reached. This implies a
more beneficial outcome in the disease prognosis if the serocon-
version is instantaneous rather then gradual. This result is in
agreement with biological studies that show that gradual loss of
HBeAg-positive virus through intermediate mutations [14] or
through persistence of HBeAg-positive virus strains through
integration into hepatocyte genome [19] can harm the patient.
In the mutation model, immune tolerance is lost when the
activation rate of T-cells specific for HBeAg-negative virus at the
carrying capacity of the virus is larger than their death rate.
Furthermore, the removal of HBeAg-positive virus and HBeAg
and subsequent liver damage is driven by the mutation rate. The
highest liver cell loss takes place when half of the HBeAg-positive
virus mutates. If more than 99:9% hepatocytes mutate over a long
period of time, then the liver damage is insignificant. This implies
that instantaneous loss of HBeAg through mutation is beneficial to
the disease outcome leading to inactive carrier states as previously
suggested [19]. Our mutation model makes three assumptions: (1)
that the percent w of strain Vp that mutates to give rise to virus Vn
is constant; (2) that there is no cross-reactivity between the T-cell
response to HBeAg-negative virus and the HBeAg-positive virus,
and (3) that the dynamics of hepatocytes infection and viral
production can be incorporated into a single virus equation. Based
on the asymptotic analysis of (6–10), varying w does not affect the
stability of the tolerance state STn. It does affect whether e-positive
virus will coexist with e-negative virus and HBeAg would be
present or e-positive virus and e-antigen would be lost. Therefore,
relaxing the first assumption is unlikely to dramatically affect our
conclusions. The second assumption can be addressed by
modifying the mutation model to account for T-cells cross-
reactivity. If we assume that HBeAg-positive and HBeAg-negative
virus replicate at the same rates and cross-reactive T-cells remove
HBeAg-positive virus at a higher rate than HBeAg-negative virus
(a phenomenon known as original antigenic sin [35]), then
HBeAg-positive virus is removed completely, regardless of
mutation rate when the cross-reactive T-cell activation rate at
the virus carrying capacity is greater than its death rate. In this
case, the patient enters an inactive carrier stage where liver
damage is minimal. The third assumption can be addressed by
modifying the mutation model to account for the dynamics of
uninfected and infected hepatocytes. One important biological
assumption is that unlike acute HBV infection, where the majority
of the liver gets infected by HBV, chronic HBV infection leads to a
smaller percentage of infected hepatocytes [36,37]. Because of this,
Figure 7. Cumulative % liver loss as a function of mutation rate w for VwK. The liver loss is computed as asm(t)/L where asm is given by (16).
The bottom figure is computed as ahm(t)/L where ahm is given by (17) for ww0:999. L~13:6|106 represents the total hepatocytes density in the
liver, and t~100. The rest of parameters are given in table 1.
doi:10.1371/journal.pone.0039591.g007
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following continuous mutation, to become the dominant virus in
the body. We compared the stability results for the extended
model with the results predicted by the mutation model presented
in the paper and found that increasing model complexity does not
change the results (not shown). However, while we still obtain high
liver damage for intermediary mutation rates, the peak of liver loss
shifted to the right and occurs for 75% rather than 50% mutation
rate (not shown). This result may be due to the fact that delay in
hepatocyte infection and T lymphocytes specific for HBeAg-
negative virus activation may be accounted by the extended
model. Further analysis is needed to validate these conjectures.
Our model predicts that for small mutation rates the level of
HBeAg-positive virus is 3|107 copies per ml. If we take into
account the hypothesis that loss of HBeAg through mutations in
the core promoter can cause HBeAg seroconversion [18], and
transform the mutation model to account for e-antigen loss at rate
d(1zcIg) with cIg~1000 being the overall HBeAg removal by
antibody, then the HBeAg-positive virus (which accounts for the
majority of HBV DNA) decreases by one order magnitude to
5|106 copies per ml. However, the overall dynamics and quantity
of the liver loss remains unchanged, with high levels of liver cell
death for intermediate mutation rates.
An interesting implication of this model is that tolerance and
loss of tolerance are not affected by the virus replication rate (rp)
and T-cells killing rate (mp), as the size of V does not depend on
these parameters. The independence of tolerance loss on T-cell
killing rate is preserved in both seroconversion and mutation
models. This suggests that the e-antigen induces T-cell tolerance
by reducing their proliferative but not their killing capabilities.
Our model does not consider all host and viral mechanisms
associated with hepatitis B virus tolerance. While we assumed that
T-cells inactivity is solely mediated by e-antigen, it has been
suggested that the core antigen (HBcAg) may act as a tolerogen as
well [11]. Furthermore, recent studies have shown that the
proliferative capacities of CD8 T-cells during chronic hepatitis are
affected by increased regulatory T-cell (Tregs) levels [38,39] and
by an imbalance between Tregs and T helper cells that produce
interleukin-17 (Th17) [40]. Further work is needed to account for
the quantitative contributions of each of these factors. Finally, we
ignored the age of tolerance loss, which may provide insight into
the correlation between the age of the patient at immune
activation and the severity of infection [14,21]. In spite of these
simplifications, our study makes predictions on the type of
dynamics expected during tolerance loss. Such understanding is
essential in determining whether its occurrence is desirable and
whether we can control immune activation so as to minimize long
term negative effects on the patient’s liver.
Supporting Information
Figure S1 Bifurcation diagrams showing the change in
the HBeAg-positive virus steady state (top panel) and
HBeAg-specific T cells steady state (lower panel) as a
function of antibody levels Ig for VwK. We used parameters
from table 1, p~5:9|10{8 and c~1. The transition from
tolerance to immune activation is marked by vertical lines.
(TIF)
Figure S2 Numerical curves showing the transition
from an immune tolerant HBeAg-positive virus Vp virus
given by ST stable in model (1–3) (dash lines) to an
immune tolerant mutant HBeAg-negative virus Vn virus
given by STn stable in model (6–10) (solid lines). The
transition is marked by vertical lines. Parameters are rp~1, rn~1,
mp~10{1, mn~10{1, p~5:9|10{8, d~0:3, ap~10{7,
an~10{9, s~1, d~0:5, w~0:7 and K~108. The tolerance
steady states of the one-virus model are used as initial conditions
for the two virus model with Vn(500)~0:3 and Tn(500)~10.
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